Brightpath Biotherapeutics Co. Ltd. filed an Investigational New Drug (IND) application with the FDA to initiate a U.S. phase I trial of BP-2202 for multiple myeloma, under NCT07667868. The filing represents a key regulatory step for a candidate moving from discovery into early human testing in the United States. Phase I studies typically assess safety, tolerability, pharmacokinetics, and preliminary biological activity. For the broader myeloma landscape, new first-in-human entries remain closely watched given the crowded but still expanding set of mechanisms and combination strategies. The next milestone will be FDA clearance and trial start, followed by initial dose-escalation and any early efficacy signals as cohorts expand.